{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"157","value":"92.2"},{"groupId":"OG001","spread":"106","value":"120"},{"groupId":"OG002","spread":"103","value":"144"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"C1 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"106","value":"190"},{"groupId":"OG001","spread":"67.8","value":"151"},{"groupId":"OG002","spread":"18.2","value":"323"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"C2 D1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"description":"Cmax of rebastinib","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Dose escalation with rebastinib 50 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG000","title":"Part 1 Cohort 1 Escalation Rebastinib 50 mg + Carboplatin AUC5"},{"description":"Dose escalation with rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG001","title":"Part 1 Cohort 2 Escalation Rebastinib 100 mg + Carboplatin AUC5"},{"description":"Dose escalation with rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC6 at Day 1 of each 21-day cycle.","id":"OG002","title":"Part 1 Cohort 3 Escalation Rebastinib 100 mg + Carboplatin AUC6"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Part 1 participants who received any study drug and had evaluable Cmax data at each timepoint.","reportingStatus":"POSTED","timeFrame":"Part 1: Cycle (C) 1 Day (D) 1, C2 D1 (Cycle = 21 Days)","title":"Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Rebastinib (Part 1)","type":"SECONDARY","unitOfMeasure":"Nanograms per milliliter (ng/mL)"}